JP2005508923A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005508923A5 JP2005508923A5 JP2003532058A JP2003532058A JP2005508923A5 JP 2005508923 A5 JP2005508923 A5 JP 2005508923A5 JP 2003532058 A JP2003532058 A JP 2003532058A JP 2003532058 A JP2003532058 A JP 2003532058A JP 2005508923 A5 JP2005508923 A5 JP 2005508923A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- quinolin
- compound
- compound according
- pyrrolidin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 29
- 125000000217 alkyl group Chemical group 0.000 claims 18
- 229910052739 hydrogen Inorganic materials 0.000 claims 12
- 239000001257 hydrogen Substances 0.000 claims 12
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 11
- 125000000623 heterocyclic group Chemical group 0.000 claims 8
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical group C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims 7
- 229910052757 nitrogen Inorganic materials 0.000 claims 7
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 7
- 239000008194 pharmaceutical composition Substances 0.000 claims 7
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims 6
- 125000003545 alkoxy group Chemical group 0.000 claims 6
- 229910052736 halogen Inorganic materials 0.000 claims 6
- 150000002367 halogens Chemical class 0.000 claims 6
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 6
- 229940086609 Lipase inhibitor Drugs 0.000 claims 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 5
- 125000001424 substituent group Chemical group 0.000 claims 5
- 208000008589 Obesity Diseases 0.000 claims 4
- 125000000753 cycloalkyl group Chemical group 0.000 claims 4
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims 4
- 238000004519 manufacturing process Methods 0.000 claims 4
- 235000020824 obesity Nutrition 0.000 claims 4
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 3
- 125000003118 aryl group Chemical group 0.000 claims 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 3
- 125000004093 cyano group Chemical group *C#N 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 125000005842 heteroatom Chemical group 0.000 claims 3
- AHLBNYSZXLDEJQ-FWEHEUNISA-N orlistat Chemical group CCCCCCCCCCC[C@H](OC(=O)[C@H](CC(C)C)NC=O)C[C@@H]1OC(=O)[C@H]1CCCCCC AHLBNYSZXLDEJQ-FWEHEUNISA-N 0.000 claims 3
- 229960001243 orlistat Drugs 0.000 claims 3
- 229910052760 oxygen Inorganic materials 0.000 claims 3
- 239000001301 oxygen Chemical group 0.000 claims 3
- 230000002265 prevention Effects 0.000 claims 3
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims 3
- 229910052717 sulfur Chemical group 0.000 claims 3
- 239000011593 sulfur Chemical group 0.000 claims 3
- 208000024172 Cardiovascular disease Diseases 0.000 claims 2
- 208000030814 Eating disease Diseases 0.000 claims 2
- 208000019454 Feeding and Eating disease Diseases 0.000 claims 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 claims 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 claims 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims 2
- 208000001647 Renal Insufficiency Diseases 0.000 claims 2
- 125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 claims 2
- 206010003246 arthritis Diseases 0.000 claims 2
- 125000003710 aryl alkyl group Chemical group 0.000 claims 2
- 125000001246 bromo group Chemical group Br* 0.000 claims 2
- 125000001309 chloro group Chemical group Cl* 0.000 claims 2
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims 2
- 206010012601 diabetes mellitus Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 235000014632 disordered eating Nutrition 0.000 claims 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 2
- 125000002346 iodo group Chemical group I* 0.000 claims 2
- 201000006370 kidney failure Diseases 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 2
- OFCMJTXCXQZZHQ-UHFFFAOYSA-N (2,6-dimethyl-4-pyrrolidin-1-ylquinolin-7-yl)methanol Chemical compound C=12C=C(C)C(CO)=CC2=NC(C)=CC=1N1CCCC1 OFCMJTXCXQZZHQ-UHFFFAOYSA-N 0.000 claims 1
- FQUYSHZXSKYCSY-UHFFFAOYSA-N 1,4-diazepane Chemical group C1CNCCNC1 FQUYSHZXSKYCSY-UHFFFAOYSA-N 0.000 claims 1
- CHRSSSYOZYZOFK-UHFFFAOYSA-N 2-[(2-methyl-4-pyrrolidin-1-ylquinolin-7-yl)methoxy]benzonitrile Chemical compound C=12C=CC(COC=3C(=CC=CC=3)C#N)=CC2=NC(C)=CC=1N1CCCC1 CHRSSSYOZYZOFK-UHFFFAOYSA-N 0.000 claims 1
- XATCREPNDSEOGK-UHFFFAOYSA-N 2-chloro-4-[(2-methyl-4-pyrrolidin-1-ylquinolin-7-yl)methoxy]benzonitrile Chemical compound C=12C=CC(COC=3C=C(Cl)C(C#N)=CC=3)=CC2=NC(C)=CC=1N1CCCC1 XATCREPNDSEOGK-UHFFFAOYSA-N 0.000 claims 1
- SNRXFJAQZXURJY-UHFFFAOYSA-N 2-methyl-7-(pyridin-4-yloxymethyl)-4-pyrrolidin-1-ylquinoline Chemical compound C=12C=CC(COC=3C=CN=CC=3)=CC2=NC(C)=CC=1N1CCCC1 SNRXFJAQZXURJY-UHFFFAOYSA-N 0.000 claims 1
- OSHRLFZAABJWIA-UHFFFAOYSA-N 4-[(2,6-dimethyl-4-pyrrolidin-1-ylquinolin-7-yl)methoxy]benzonitrile Chemical compound C=12C=C(C)C(COC=3C=CC(=CC=3)C#N)=CC2=NC(C)=CC=1N1CCCC1 OSHRLFZAABJWIA-UHFFFAOYSA-N 0.000 claims 1
- FBJUQLXTVWMSMQ-UHFFFAOYSA-N 4-[(2,6-dimethyl-4-pyrrolidin-1-ylquinolin-7-yl)methylamino]benzonitrile Chemical compound C=12C=C(C)C(CNC=3C=CC(=CC=3)C#N)=CC2=NC(C)=CC=1N1CCCC1 FBJUQLXTVWMSMQ-UHFFFAOYSA-N 0.000 claims 1
- FQMBNIOZTFMQEB-UHFFFAOYSA-N 4-[(2-methyl-4-pyrrolidin-1-ylquinolin-7-yl)methoxy]-2-(trifluoromethyl)benzonitrile Chemical compound C=12C=CC(COC=3C=C(C(C#N)=CC=3)C(F)(F)F)=CC2=NC(C)=CC=1N1CCCC1 FQMBNIOZTFMQEB-UHFFFAOYSA-N 0.000 claims 1
- VORUYQGEUJBGHH-UHFFFAOYSA-N 4-[(2-methyl-4-pyrrolidin-1-ylquinolin-7-yl)methoxy]benzene-1,2-dicarbonitrile Chemical compound C=12C=CC(COC=3C=C(C(C#N)=CC=3)C#N)=CC2=NC(C)=CC=1N1CCCC1 VORUYQGEUJBGHH-UHFFFAOYSA-N 0.000 claims 1
- YRGQRXMURUGZDN-UHFFFAOYSA-N 4-[(2-methyl-4-pyrrolidin-1-ylquinolin-7-yl)methoxy]benzonitrile Chemical compound C=12C=CC(COC=3C=CC(=CC=3)C#N)=CC2=NC(C)=CC=1N1CCCC1 YRGQRXMURUGZDN-UHFFFAOYSA-N 0.000 claims 1
- ZETVYJWZAJSNLN-UHFFFAOYSA-N 4-[(2-methyl-4-pyrrolidin-1-ylquinolin-7-yl)methylamino]-2-(trifluoromethyl)benzonitrile Chemical compound C=12C=CC(CNC=3C=C(C(C#N)=CC=3)C(F)(F)F)=CC2=NC(C)=CC=1N1CCCC1 ZETVYJWZAJSNLN-UHFFFAOYSA-N 0.000 claims 1
- BZCCJWGPBJXSFD-UHFFFAOYSA-N 4-[(2-methyl-4-pyrrolidin-1-ylquinolin-7-yl)methylamino]benzonitrile Chemical compound C=12C=CC(CNC=3C=CC(=CC=3)C#N)=CC2=NC(C)=CC=1N1CCCC1 BZCCJWGPBJXSFD-UHFFFAOYSA-N 0.000 claims 1
- RVEDDNXDVZBQNM-UHFFFAOYSA-N 4-[[4-(azepan-1-yl)-2-methylquinolin-7-yl]methoxy]benzonitrile Chemical compound C=12C=CC(COC=3C=CC(=CC=3)C#N)=CC2=NC(C)=CC=1N1CCCCCC1 RVEDDNXDVZBQNM-UHFFFAOYSA-N 0.000 claims 1
- UXMOAHLHPOHSPS-QFIPXVFZSA-N 4-[[4-[(3s)-3-ethoxypyrrolidin-1-yl]-2,6-dimethylquinolin-7-yl]methoxy]benzonitrile Chemical compound C1[C@@H](OCC)CCN1C1=CC(C)=NC2=CC(COC=3C=CC(=CC=3)C#N)=C(C)C=C12 UXMOAHLHPOHSPS-QFIPXVFZSA-N 0.000 claims 1
- BUGFCSYGBDDVKK-UHFFFAOYSA-N C(CCC)(=O)N.CC1=NC2=CC(=CC=C2C(=C1)N1CCCC1)C(=O)O Chemical compound C(CCC)(=O)N.CC1=NC2=CC(=CC=C2C(=C1)N1CCCC1)C(=O)O BUGFCSYGBDDVKK-UHFFFAOYSA-N 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 229940127470 Lipase Inhibitors Drugs 0.000 claims 1
- SELLRXHGEKIKKL-UHFFFAOYSA-N [4-(azepan-1-yl)-2-methylquinolin-7-yl]methanol Chemical compound C=12C=CC(CO)=CC2=NC(C)=CC=1N1CCCCCC1 SELLRXHGEKIKKL-UHFFFAOYSA-N 0.000 claims 1
- LGQODQYMJCBWSG-HNNXBMFYSA-N [4-[(3s)-3-ethoxypyrrolidin-1-yl]-2,6-dimethylquinolin-7-yl]methanol Chemical compound C1[C@@H](OCC)CCN1C1=CC(C)=NC2=CC(CO)=C(C)C=C12 LGQODQYMJCBWSG-HNNXBMFYSA-N 0.000 claims 1
- 239000013543 active substance Substances 0.000 claims 1
- 150000001412 amines Chemical class 0.000 claims 1
- ZSIQJIWKELUFRJ-UHFFFAOYSA-N azepane Chemical compound C1CCCNCC1 ZSIQJIWKELUFRJ-UHFFFAOYSA-N 0.000 claims 1
- JFDZBHWFFUWGJE-UHFFFAOYSA-N benzonitrile Substances N#CC1=CC=CC=C1 JFDZBHWFFUWGJE-UHFFFAOYSA-N 0.000 claims 1
- 125000005112 cycloalkylalkoxy group Chemical group 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 150000002148 esters Chemical class 0.000 claims 1
- 150000004678 hydrides Chemical class 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 1
- 125000004076 pyridyl group Chemical group 0.000 claims 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 1
- -1 pyrrolidinylcarbonyl Chemical group 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 claims 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP01123496 | 2001-09-28 | ||
| PCT/EP2002/010618 WO2003028726A1 (en) | 2001-09-28 | 2002-09-20 | Quinoline derivatives as neuropeptide y antagonists |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2005508923A JP2005508923A (ja) | 2005-04-07 |
| JP2005508923A5 true JP2005508923A5 (enExample) | 2005-12-22 |
| JP4187652B2 JP4187652B2 (ja) | 2008-11-26 |
Family
ID=8178804
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003532058A Expired - Fee Related JP4187652B2 (ja) | 2001-09-28 | 2002-09-20 | ニューロペプチドｙアンタゴニストとしてのキノリン誘導体 |
Country Status (23)
| Country | Link |
|---|---|
| US (4) | US6787558B2 (enExample) |
| EP (1) | EP1432421A1 (enExample) |
| JP (1) | JP4187652B2 (enExample) |
| KR (1) | KR100605765B1 (enExample) |
| CN (1) | CN1289087C (enExample) |
| AR (1) | AR040626A1 (enExample) |
| AU (1) | AU2002342735B2 (enExample) |
| BR (1) | BR0212929A (enExample) |
| CA (1) | CA2460865C (enExample) |
| GT (1) | GT200200197A (enExample) |
| HR (1) | HRP20040272A2 (enExample) |
| HU (1) | HUP0401481A2 (enExample) |
| IL (1) | IL160750A0 (enExample) |
| MX (1) | MXPA04002825A (enExample) |
| NO (1) | NO20041235L (enExample) |
| NZ (1) | NZ531517A (enExample) |
| PA (1) | PA8555401A1 (enExample) |
| PE (1) | PE20030603A1 (enExample) |
| PL (1) | PL370414A1 (enExample) |
| RU (1) | RU2300531C2 (enExample) |
| UY (1) | UY27462A1 (enExample) |
| WO (1) | WO2003028726A1 (enExample) |
| ZA (1) | ZA200402359B (enExample) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6900226B2 (en) * | 2000-09-06 | 2005-05-31 | Hoffman-La Roche Inc. | Neuropeptide Y antagonists |
| US7772188B2 (en) | 2003-01-28 | 2010-08-10 | Ironwood Pharmaceuticals, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
| EP1734963A4 (en) | 2004-04-02 | 2008-06-18 | Merck & Co Inc | METHOD FOR TREATING PEOPLE WITH METABOLIC AND ANTHROPOMETRIC DISORDER |
| BRPI0811745B1 (pt) * | 2007-05-17 | 2019-06-04 | Helperby Therapeutics Limited | Compostos de 4-(pirrolidin-1-il)quinolina, uso e processo para a preparação dos mesmos, formulação farmacêutica -- |
| US8969514B2 (en) | 2007-06-04 | 2015-03-03 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases |
| MX354786B (es) | 2007-06-04 | 2018-03-21 | Synergy Pharmaceuticals Inc | Agonistas de guanilato ciclasa utiles para el tratamiento de trastornos gastrointestinales, inflamacion, cancer y otros trastornos. |
| CA2713998A1 (en) * | 2008-01-28 | 2009-08-06 | Janssen Pharmaceutica N.V. | 6-substituted-thio-2-amino-quinoline derivatives useful as inhibitors of.beta.-secretase (bace) |
| CA2726917C (en) | 2008-06-04 | 2018-06-26 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
| EP2321341B1 (en) | 2008-07-16 | 2017-02-22 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders |
| US8410284B2 (en) | 2008-10-22 | 2013-04-02 | Merck Sharp & Dohme Corp | Cyclic benzimidazole derivatives useful as anti-diabetic agents |
| CA2741672A1 (en) | 2008-10-31 | 2010-05-06 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
| AU2011218830B2 (en) | 2010-02-25 | 2014-07-24 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
| US9616097B2 (en) | 2010-09-15 | 2017-04-11 | Synergy Pharmaceuticals, Inc. | Formulations of guanylate cyclase C agonists and methods of use |
| CA2826649C (en) | 2011-02-25 | 2016-07-26 | Merck Sharp & Dohme Corp. | Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents |
| RU2015106909A (ru) | 2012-08-02 | 2016-09-27 | Мерк Шарп И Доум Корп. | Антидиабетические трициклические соединения |
| BR112015019836A2 (pt) | 2013-02-22 | 2017-07-18 | Merck Sharp & Dohme | composto, composição farmacêutica, e, uso de um composto |
| EP2970119B1 (en) | 2013-03-14 | 2021-11-03 | Merck Sharp & Dohme Corp. | Novel indole derivatives useful as anti-diabetic agents |
| WO2014151200A2 (en) | 2013-03-15 | 2014-09-25 | Synergy Pharmaceuticals Inc. | Compositions useful for the treatment of gastrointestinal disorders |
| JP2016514671A (ja) | 2013-03-15 | 2016-05-23 | シナジー ファーマシューティカルズ インコーポレイテッド | グアニル酸シクラーゼのアゴニストおよびその使用 |
| CN105764916B (zh) | 2013-06-05 | 2021-05-18 | 博士医疗爱尔兰有限公司 | 鸟苷酸环化酶c的超纯激动剂、制备和使用所述激动剂的方法 |
| WO2015051496A1 (en) | 2013-10-08 | 2015-04-16 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
| US9212144B2 (en) * | 2014-01-10 | 2015-12-15 | Northwestern University | 2-aminoquinoline-based compounds for potent and selective neuronal nitric oxide synthase inhibition |
| US9663468B2 (en) | 2014-01-10 | 2017-05-30 | Northwestern University | 2-aminoquinoline-based compounds for potent and selective neuronal nitric oxide synthase inhibition |
| CA3023032A1 (en) * | 2016-05-04 | 2017-11-09 | Genoscience Pharma | Substituted 2,4-diamino-quinoline derivatives for use in the treatment of proliferative diseases |
| US11072602B2 (en) | 2016-12-06 | 2021-07-27 | Merck Sharp & Dohme Corp. | Antidiabetic heterocyclic compounds |
| WO2018118670A1 (en) | 2016-12-20 | 2018-06-28 | Merck Sharp & Dohme Corp. | Antidiabetic spirochroman compounds |
| US12577217B2 (en) | 2019-01-08 | 2026-03-17 | Kyorin Pharmaceutical Co., Ltd. | 15-PGDH inhibitor |
| JP7532385B2 (ja) * | 2019-01-31 | 2024-08-13 | 杏林製薬株式会社 | １５－ｐｇｄｈ阻害薬 |
| WO2020231739A2 (en) * | 2019-05-10 | 2020-11-19 | Antidote Ip Holdings, Llc | Compounds and methods for treating cancer |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3272824A (en) | 1962-12-06 | 1966-09-13 | Norwich Pharma Co | 4-amino-6, 7-di(lower) alkoxyquinolines |
| US4035367A (en) | 1974-09-09 | 1977-07-12 | Sandoz, Inc. | Hydroxyalkyl-substituted-amino-quinolines |
| CA1247547A (en) | 1983-06-22 | 1988-12-28 | Paul Hadvary | Leucine derivatives |
| CA1270837A (en) | 1984-12-21 | 1990-06-26 | Hoffmann-La Roche Limited | Oxetanones |
| CA1328881C (en) | 1984-12-21 | 1994-04-26 | Pierre Barbier | Process for the manufacture of oxetanones |
| BR8606663A (pt) * | 1985-05-07 | 1987-08-11 | Alkaloida Vegyeszeti Gyar | Derivados de triazolil-quinolina |
| CA2035972C (en) | 1990-02-23 | 2006-07-11 | Martin Karpf | Process for the preparation of oxetanones |
| US5274143A (en) | 1991-07-23 | 1993-12-28 | Hoffmann-La Roche Inc. | Process for the preparation of (R)-3-hexyl-5,6-dihydro-4-hydroxy-6-undecyl-2H-pyran-2-one and (R)-5,6-dihydro-6-undecyl-2H-pyran-2,4(3H)-dione |
| AU719392B2 (en) | 1996-10-01 | 2000-05-11 | Kyowa Hakko Kirin Co., Ltd. | Nitrogen-containing heterocyclic compounds |
| US6004996A (en) | 1997-02-05 | 1999-12-21 | Hoffman-La Roche Inc. | Tetrahydrolipstatin containing compositions |
| US6267952B1 (en) | 1998-01-09 | 2001-07-31 | Geltex Pharmaceuticals, Inc. | Lipase inhibiting polymers |
| US6199042B1 (en) * | 1998-06-19 | 2001-03-06 | L&H Applications Usa, Inc. | Reading system |
| CA2340056C (en) | 1998-08-14 | 2007-01-09 | F. Hoffmann-La Roche Ag | Pharmaceutical compositions containing lipase inhibitors |
| PT1105123E (pt) | 1998-08-14 | 2004-08-31 | Hoffmann La Roche | Composicoes farmaceuticas contendo inibidores da lipase e quitosano |
| FR2795726A1 (fr) * | 1999-06-30 | 2001-01-05 | Aventis Cropscience Sa | Nouveaux pyrazoles fongicides |
| ES2258476T3 (es) | 1999-09-30 | 2006-09-01 | Neurogen Corporation | Ciertos heterociclos sustituidos con alquilendiaminas. |
| US6900226B2 (en) | 2000-09-06 | 2005-05-31 | Hoffman-La Roche Inc. | Neuropeptide Y antagonists |
-
2002
- 2002-09-19 US US10/247,009 patent/US6787558B2/en not_active Expired - Fee Related
- 2002-09-20 PL PL02370414A patent/PL370414A1/xx not_active Application Discontinuation
- 2002-09-20 CA CA002460865A patent/CA2460865C/en not_active Expired - Fee Related
- 2002-09-20 BR BR0212929-9A patent/BR0212929A/pt not_active IP Right Cessation
- 2002-09-20 EP EP02779399A patent/EP1432421A1/en not_active Withdrawn
- 2002-09-20 RU RU2004113207/04A patent/RU2300531C2/ru not_active IP Right Cessation
- 2002-09-20 MX MXPA04002825A patent/MXPA04002825A/es active IP Right Grant
- 2002-09-20 NZ NZ531517A patent/NZ531517A/en unknown
- 2002-09-20 HR HR20040272A patent/HRP20040272A2/hr not_active Application Discontinuation
- 2002-09-20 JP JP2003532058A patent/JP4187652B2/ja not_active Expired - Fee Related
- 2002-09-20 WO PCT/EP2002/010618 patent/WO2003028726A1/en not_active Ceased
- 2002-09-20 CN CNB028191919A patent/CN1289087C/zh not_active Expired - Fee Related
- 2002-09-20 AU AU2002342735A patent/AU2002342735B2/en not_active Ceased
- 2002-09-20 HU HU0401481A patent/HUP0401481A2/hu unknown
- 2002-09-20 KR KR1020047004591A patent/KR100605765B1/ko not_active Expired - Fee Related
- 2002-09-20 IL IL16075002A patent/IL160750A0/xx unknown
- 2002-09-25 PA PA20028555401A patent/PA8555401A1/es unknown
- 2002-09-26 PE PE2002000952A patent/PE20030603A1/es not_active Application Discontinuation
- 2002-09-27 AR AR20020103663A patent/AR040626A1/es not_active Application Discontinuation
- 2002-09-27 UY UY27462A patent/UY27462A1/es not_active Application Discontinuation
- 2002-09-27 GT GT200200197A patent/GT200200197A/es unknown
-
2004
- 2004-03-24 NO NO20041235A patent/NO20041235L/no not_active Application Discontinuation
- 2004-03-25 ZA ZA200402359A patent/ZA200402359B/en unknown
- 2004-07-22 US US10/896,445 patent/US7012073B2/en not_active Expired - Fee Related
-
2005
- 2005-11-10 US US11/272,207 patent/US7064134B2/en not_active Expired - Fee Related
-
2006
- 2006-03-16 US US11/376,976 patent/US7166589B2/en not_active Expired - Fee Related